Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Research indicates its potential to interact with beta-adrenergic pathways, amplifying beta(3)-AR receptor sensitivity and enhancing fat oxidation and energy expenditure without inducing IGF-1 production
Your body produces it naturally, with levels highest in youth and declining with age (the same pattern as every other compound in this article)
Avoid it if you have a known allergy to thiamine, pyridoxine, cyanocobalamin, or cobalt
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
When you are deficient, symptoms can include fatigue, weakness, and brain fog
AOD-9604 accelerates fat loss. The scientific gap There are no high-quality randomized trials demonstrating that semaglutide + AOD-9604 produces better outcomes than semaglutide alone, or that it improves lean mass retention, resting metabolic rate, or long-term weight maintenance
